FBH1 protects melanocytes from transformation and is deregulated in melanomas

Cell Cycle

Volumn 12, Issue 7, 2013, Pages 1128-1132

  Jeong, Yeon Tae ^a   Cermak, Lukas ^a,b   Guijarro, Maria V ^a   Hernando, Eva ^a   Pagano, Michele ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

DNA replication stress; F box protein; FBH1; Helicase; Melanoma

Indexed keywords

FBH1 HELICASE; HELICASE; UNCLASSIFIED DRUG;

ARTICLE; CELL PROTECTION; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; DNA DAMAGE CHECKPOINT; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA CELL; ULTRAVIOLET IRRADIATION;

EID: 84875892495     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.24165     Document Type: Article

References (15)

1. Jeong YT, Rossi M, Cermak L, Saraf A, Florens L, Washburn MP, et al. FBH1 promotes DNA double-strand breakage and apoptosis in response to DNA replication stress. J Cell Biol 2013; 200:141- 9; PMID:23319600; http://dx.doi.org/10.1083/jcb.201209002
2. Fugger K, Mistrik M, Danielsen JR, Dinant C, Falck J, Bartek J, et al. Human Fbh1 helicase contributes to genome maintenance via pro- and antirecombinase activities. J Cell Biol 2009; 186:655- 63; PMID:19736316; http://dx.doi.org/10.1083/jcb.200812138
3. Rose AE, Poliseno L, Wang J, Clark M, Pearlman A, Wang G, et al. Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. Cancer Res 2011; 71:2561-71; PMID:21343389; http://dx.doi.org/10.1158/0008- 5472.CAN-10-2958
4. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002; 30:207- 10; PMID:11752295; http://dx.doi.org/10.1093/nar/30.1.207
5. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988; 48:589-601; PMID:3335022
6. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012; 485:502-6; PMID:22622578
7. Sutherland BM, Cimino JS, Delihas N, Shih AG, Oliver RP. Ultraviolet light-induced transformation of human cells to anchorage-independent growth. Cancer Res 1980; 40:1934-9; PMID:7371028
8. Scott KL, Nogueira C, Heffernan TP, van Doorn R, Dhakal S, Hanna JA, et al. Proinvasion metastasis drivers in early-stage melanoma are oncogenes. Cancer Cell 2011; 20:92-103; PMID:21741599; http://dx.doi. org/10.1016/j.ccr.2011.05. 025
9. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 2010; 40:179- 204; PMID:20965415; http://dx.doi.org/10. 1016/j. molcel.2010.09.019
10. Batista LF, Kaina B, Meneghini R, Menck CF. How DNA lesions are turned into powerful killing structures: insights from UV-induced apoptosis. Mutat Res 2009; 681:197-208; PMID:18845270; http://dx.doi. org/10.1016/j.mrrev.2008.09.001
11. Shao J, Zhou B, Chu B, Yen Y. Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets 2006; 6:409-31; PMID:16918309; http://dx.doi.org/10.2174/156800906777723949
12. D'Angiolella V, Donato V, Vijayakumar S, Saraf A, Florens L, Washburn MP, et al. SCF(Cyclin F) controls centrosome homeostasis and mitotic fidelity through CP110 degradation. Nature 2010; 466:138- 42; PMID:20596027; http://dx.doi.org/10.1038/nature09140
13. D'Angiolella V, Donato V, Forrester FM, Jeong YT, Pellacani C, Kudo Y, et al. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell 2012; 149:1023- 34; PMID:22632967; http://dx.doi.org/10.1016/j. cell.2012.03.043
14. Busino L, Bassermann F, Maiolica A, Lee C, Nolan PM, Godinho SI, et al. SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins. Science 2007; 316:900- 4; PMID:17463251; http://dx.doi.org/10.1126/science. 1141194
15. Duan S, Cermak L, Pagan JK, Rossi M, Martinengo C, di Celle PF, et al. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature 2012; 481:90-3; PMID:22113614; http://dx.doi.org/10.1038/ nature10688